Earnshaw SR - Search Results

1

Optimal allocation of resources across four interventions for type 2 diabetes.

Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KM, Williamson DF, Gregg E, Zhang P. Earnshaw SR, et al. Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S80-91. doi: 10.1177/027298902237704. Med Decis Making. 2002. PMID: 12369234

2

Integer/linear mathematical programming models: a tool for allocating healthcare resources.

Earnshaw SR, Dennett SL. Earnshaw SR, et al. Pharmacoeconomics. 2003;21(12):839-51. doi: 10.2165/00019053-200321120-00001. Pharmacoeconomics. 2003. PMID: 12908840

3

A linear programming model for allocating HIV prevention funds with state agencies: a pilot study.

Earnshaw SR, Hicks K, Richter A, Honeycutt A. Earnshaw SR, et al. Health Care Manag Sci. 2007 Sep;10(3):239-52. doi: 10.1007/s10729-007-9017-8. Health Care Manag Sci. 2007. PMID: 17695135

4

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.

Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Earnshaw SR, et al. Curr Med Res Opin. 2007 Oct;23(10):2517-29. doi: 10.1185/030079907X226339. Curr Med Res Opin. 2007. PMID: 17825128 Clinical Trial.

5

Allocating HIV prevention resources: a tool for state and local decision making.

Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Richter A, et al. Among authors: earnshaw sr. Health Policy. 2008 Sep;87(3):342-9. doi: 10.1016/j.healthpol.2008.01.008. Epub 2008 Mar 14. Health Policy. 2008. PMID: 18342388

6

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Earnshaw SR, et al. Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525. Arch Intern Med. 2011. PMID: 21325111 Free PMC article.

7

Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.

Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Earnshaw SR, et al. Stroke. 2006 Nov;37(11):2751-8. doi: 10.1161/01.STR.0000246611.21999.5d. Epub 2006 Sep 28. Stroke. 2006. PMID: 17008607

8

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S. Earnshaw SR, et al. Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5. doi: 10.1016/j.clinthera.2007.09.001. Clin Ther. 2007. PMID: 18035208

9

Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.

Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Earnshaw SR, et al. J Am Soc Nephrol. 2008 Sep;19(9):1807-16. doi: 10.1681/ASN.2007040495. Epub 2008 Jun 18. J Am Soc Nephrol. 2008. PMID: 18562571 Free PMC article.

10

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Earnshaw SR, et al. Respir Med. 2009 Jan;103(1):12-21. doi: 10.1016/j.rmed.2008.10.005. Epub 2008 Nov 17. Respir Med. 2009. PMID: 19010652 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters